BETTER MEDICINE
FOR ALL

MedinCell is a clinical- and commercial-stage biopharmaceutical company. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options.

Latest news

Teva announces recruitment completion of phase 3 clinical study of mdc-TJK

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.